Induction of radiosensitization by indolocarbazole derivatives: The role of DNA topoisomerase I

Molecular Pharmacology

Volumn 66, Issue 3, 2004, Pages 553-560

  Chen, Allan Y ^a   Shih, Shyh Jen ^a   Hsiao, Michael ^b   Rothenberg, Mace L ^c   Prudhomme, Michelle ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; INDOLOCARBAZOLE DERIVATIVE; R 3; RADIOSENSITIZING AGENT; REBECCAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN MCF 7; CELL SURVIVAL; CHINESE HAMSTER; CLONOGENIC ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME DEGRADATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MAMMAL CELL; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANIMALS; BREAST NEOPLASMS; CARBAZOLES; CELL DIVISION; CHO CELLS; CRICETINAE; DNA TOPOISOMERASES, TYPE I; HUMANS; INDOLES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 4944253006     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Albright N (1987) Computer programs for the analysis of cellular survival data. Radiat Res 112:331-340.
2. Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Severe D, Riou JF, Bailly C, et al. (1997) Synthesis and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem 40:3456-3465.
3. Bailly C, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M, and Waring MJ (1998) Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol Pharmacol 53:77-87.
4. Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A, and Rubin E (1999) The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry 38:8605-8611.
5. Boothman DA, Fukunaga N, and Wang M (1994) Down-regulation of DNA topoisomerasse I in mammalian cells following ionizing radiation. Cancer Res 54:4618-4626.
6. Chang WP and Little JB (1992) Delayed reproductive death as a dominant phenotype in cell clones surviving X-irradiation. Carcinogenesis 13:923-928.
7. Chen AY, Choy H, and Rothenberg ML (1999) DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology 13:39-46.
8. Chen AY, Okunieff P, Pommier Y, and Mitchell J (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529-1536.
9. Chen AY, Yu C, Gatto B, and Liu LF (1993) DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 90:8131-8135.
10. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang J, and Fojo AT (1990) Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073-10080.
11. Cook JA and Mitchell JB (1995) Radiation and chemotherapy cytotoxicity: mechanism of resistance, in Chemoradiation: An Integrated Approach to Cancer Treatment (Madhu JJ, Flam MS, Phillips TL, Legha SS, eds) pp 159-180, Lea & Febiger, Philadelphia.
12. D'Arpa P, Beardmore C, and Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924.
13. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicolas AW, Liu LF, Silber R, and Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Wash DC) 246:1046-1048.
14. Hall E (1994) Cell survival curves, in Radiobiology for the Radiologist (Hall E, ed) 4th ed., pp 29-43, Lippincott, Philadelphia.
15. Hellman S (1997) Principles of cancer management: radiation therapy, in Cancer: Principle and Practice of Oncology (DeVita Jr, Hellman S, and Rosenberg SA eds) 5th ed., pp 307-332, Lippincott, Philadelphia.
16. Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, and Mitchell JB (1999) Principles of chemoradiation: theoretical and practical considerations. Oncology 13:11-22.
17. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878.
18. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized DNA topoisomerase I-DNA complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
19. Jeggo PA (1998) Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 150:880-S91.
20. Labourier E, Riou JF, Prudhomme M, Carrasco C, Bailly C, and Tazi J (1999) Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res 59:52-55.
21. Li TK and Liu LF (2001) Tumor cell death induced by topoisomerase- targeting drugs. Annu Rev Pharmacol Toxicol 41:53-77.
22. Marder BA and Morgan WF (1993) Delayed chromosomal instability induced by DNA damage. Mol Cell Biol 13(11):6667-6677.
23. Mattern MR, Hofmann GA, McCabe FL, and Johnson RK (1991) Synergistic cell killing by ionizing radiation and DNA topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 51:5813-5816.
24. McGinn CJ, Shewach DS, and Lawrence TS (1996) Radiosensitizing nucleotides. J Natl Cancer Inst 88:1193-1203.
25. Moreau P, Anizon F, Sancelme M, Prudhomme M, Baily C, Carrasco C, Ollier M, Severe D, Riou JF, Fabbro D, et al. (1998) Synthesis and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J Med Chem 41:1631-1640.
26. Moreau P, Anizon F, Sancelme M, Prudhomme M, Severe D, Riou JF, Severe D, Riou JF, Goossens JF, Henichart JP, et al. (1999) Synthesis, mode of action, biological activities of rebeccamycin bromo derivatives. J Med Chem 42:1816-1822.
27. Moreau P, Gaillard N, Marminon C, Anizon F, Dias N, Baldeyrou B, Bailly C, Pierre A, Hickman J, Pfeiffer B, et al. (2003) Semi-synthesis, topoisomerase I and kinases inhibitory properties and antiproliferative activities of new rebeccamycin deriva-tives. Bioorg Med Chem 11:4871-4879.
28. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC (1993) Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53:1577-1582.
29. Pereira ER, Belin L, Sancelme M, Prudhomme M, Ollier M, Rapp M, Severe D, Riou JF, Fabbro D, and Meyer T (1996) Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 39:4471-4477.
30. Prudhomme M (2000) Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents. Curr Med Chem 7:1189-1212.
31. Rotman M, Aziz H, and Wasserman TH (1998) Chemotherapy and irradiation, in Principles and Practice of Radiation Oncology (Perez CA, Brady LW, eds) pp 705-722, Lippincott-Raven, Philadelphia.
32. Shih S, Phan C, Vijayakumar S, and Chen AY (2003) Modulation of DNA topoisomerase I (TOP1)-mediated radiosensitization by DNA-dependent Protein Kinase. Int J Radiat Oncol Biol Phys 57(2 Suppl):S146.
33. Sim SP, Gatto B, Yu C, Liu AA, Li TK, Rich DS, LaVoie EJ, and Liu LF (1997) Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. Biochemistry 36:13285-13291.
34. Tanizawa A, Bertrand R, Kohlhagen G, Tabuchi A, Jenkins J, and Pommier Y (1993) Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268: 25463-25468.
35. Tsao YP, Russo A, Nyamuswa G, Silber R, and Liu LF (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53:5908-5914.
36. Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, and Pommier Y (2001) Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506 and its topoisomerase I binding site. Cancer Res 61:504-508.
37. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
38. Woo MH, Vance JR, Marcos AR, Bailly C, and Bjornsti MA (2002) Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J Biol Chem 277:3813-3822.
39. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, and Nakano H (1992) Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31:12069-12075.
40. Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, and Okura A (1993) Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490-494.